25 November 2020
Independent biomedical research and treatment centre for life-threatening diseases City of Hope initiated a Phase I clinical trial of its investigational SARS-CoV-2 vaccine among healthy participants between the ages of 18 and 55 years with no prior SARS-CoV-2 infection.
Allero Therapeutics and Abbreos have announced a collaboration to clinically test the latter’s novel OroMucosal ImmunoGlobulin (OMIG) that addresses medical conditions associated with lethal amounts of pro-inflammatory cytokines and chemokines. The first focus of the initiative is to treat patients who are likely to suffer from Covid-19-associated acute respiratory distress syndrome (ARDS), and if not treated, require intensive care and ventilation.
Eli Lilly has signed a $32.5m agreement with Canada to supply 26,000 doses of its antibody drug bamlanivimab to treat Covid-19 patients. The treatment was developed by Canadian biotech company AbCellera and is expected to be supplied to Canada between December and February.
A European Union (EU) official confirmed that the European Commission has signed a vaccine supply deal with Moderna. Moderna’s mRNA-1273 vaccine candidate met its primary efficacy endpoint in a Phase III COVE study with 94.5% efficacy.
